Point Roberts, WA, NEW YORK, NY - June 10, 2014 (Investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB:AEMD).

Q: Investorideas.com

How did Aethlon Medical become involved in cancer research?

A: James A. Joyce, Chairman, CEO

Several years ago, we made a bet that particles known as exosomes, were released by tumors to suppress the immune system of cancer patients. We believed that exosomes triggered the death of the immune cells you need to combat cancer. That cancer deployed exosomes as a mechanism to survive and proliferate. It is important to recognize that when we initiated our exosome research programs, the medical community viewed these particles as nothing more than cellular debris with no biological function.

Montreal, Quebec, Canada - June 9, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma, Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that Adva-27a, the Company’s flagship oncology drug candidate was featured in Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report for its effectiveness against multidrug resistant uterine cancer cells in vitro.

The Global Markets Direct Uterine Cancer Report provides comprehensive information on the therapeutic development for Uterine Cancer, with comparative analysis, therapeutics assessment, mechanism of action, route of administration and molecule type.  The Report also reviews key players involved in the therapeutic development for Uterine Cancer including Sunshine Biopharma Inc.

New York, NY - Point Roberts, WA - June 5, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source covering leading sectors including mobile payments and payment technologies, issues a report on emerging payment technology companies Dwolla and NXT-ID, Inc. Recently, InvestorIdeas attended both the Cartes Conference held in Las Vegas and the NXT-ID, Inc.( OTCQB: NXTD ) Wocket™ smart wallet press conference held at the Plaza Hotel in New York, gaining insight on how the CEO’s of the two companies are taking a very different approach towards solving the same problem; security in the payment industry.

The ongoing breaches that consumers and businesses are faced with daily, such as those that affected Target and eBay, have incited the birth of new technologies including mobile apps, internet and cloud solutions and new digital wallets.They are all looking to protect our identity and make our financial transactions secure .

Vancouver, B.C. - June 4, 2014 (Investorideas.com Newswire) GLG Life Tech Corporation (TSX: GLG) (OTC: GLGLF) ("GLG" or the "Company"), a global leader in the agricultural and commercial development of high-quality natural sweeteners, announces that the United States Food and Drug Administration ("FDA") has issued a Generally Recognized as Safe ("GRAS") letter of no objection covering several of GLG's high-purity stevia extracts (Filing No. GRN 493). These extracts, each containing over 95% steviol glycosides (predominantly rebaudioside A and stevioside), include GLG's Rebsweet(TM) and AnySweetPLUS(TM) stevia extract products (with rebaudioside A content ranging from 50% to 85%).